A group of researchers in Taiwan has developed a new optical technology that may be able to detect an early complication of diabetes sooner, when it is more easily treated.
The secret lymphatic identity of the Schlemm’s canal
Glaucoma is one of the leading causes of blindness worldwide. A major risk factor for glaucoma is elevated eye pressure due to poor drainage of aqueous humor, the fluid that provides nutrients to…
FDA approves EYLEA Injection for treatment of Diabetic Macular Edema
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).
McDonald confirmed as new VA secretary
Robert McDonald, a West Point graduate and former CEO of Proctor and Gamble, has been confirmed as the next secretary of the Department of Veterans’ Affairs.President Barack Obama praised the Senate’s unanimous decision.
Glaucoma Treatment Study: Visual field loss, improvement comparable through 5 years
Comparable rates of visual field loss and improvement were seen until 5-year follow-up of the Collaborative Initial Glaucoma Treatment Study, at which time visual field loss became more common, according to a study. The prospective, comparative case se…
Novartis Says Alcon Glaucoma Treatment Approved in EU
Novartis said the European Commission has approved its eyecare unit Alcon’s Simbrinza eye drops suspension to decrease elevated intraocular pressure (IOP) in adults with open-angle glaucoma or ocular hypertension. International Approvals